Charles River Laboratories International (CRL) closed at $345.37 on October 23, 2026, up 1.7% from the previous close, on volume of 762,217 shares (30-day average 1,070,006).
Data as of October 23, 2026.
23-Oct-2026
Business Wire (Thu, 22-Oct 4:30 PM ET)
Midday Pulse: S&P 500 top intraday gainers
Seeking Alpha News (Wed, 21-Oct 12:46 PM ET)
Business Wire (Tue, 13-Oct 8:00 AM ET)
Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
Business Wire (Fri, 9-Oct 8:00 AM ET)
Charles River and Autolomous Partner to Transform Laboratory Execution Systems
Business Wire (Tue, 6-Oct 8:00 AM ET)
Business Wire (Thu, 24-Sep 8:00 AM ET)
Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
Business Wire (Thu, 17-Sep 8:00 AM ET)
Charles River Laboratories to Present at Morgan Stanley and Baird Conferences
Business Wire (Fri, 11-Sep 8:00 AM ET)
Business Wire (Tue, 8-Sep 8:00 AM ET)
Business Wire (Thu, 20-Aug 8:00 AM ET)
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
Charles River Laboratories International trades on the NYSE stock market under the symbol CRL.
As of October 23, 2026, CRL stock price climbed to $345.37 with 762,217 million shares trading.
CRL has a beta of 1.61, meaning it tends to be more sensitive to market movements. CRL has a correlation of 0.15 to the broad based SPY ETF.
CRL has a market cap of $17.66 billion. This is considered a Large Cap stock.
Last quarter Charles River Laboratories International reported $1 billion in Revenue and $3.02 earnings per share. This beat revenue expectation by $31 million and exceeded earnings estimates by $.29.
In the last 3 years, CRL traded as high as $351.21 and as low as $91.86.
The top ETF exchange traded funds that CRL belongs to (by Net Assets): VTI, VOO, VB, RSP, IVV.
CRL has outperformed the market in the last year with a price return of +80.9% while the SPY ETF gained +14.3%. CRL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +50.6% and +14.4%, respectively, while the SPY returned +3.2% and -2.4%, respectively.
CRL support price is $328.82 and resistance is $350.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRL shares will trade within this expected range on the day.
